Birth control sits at the center of this dementia and brain health question.
Combined estrogen-progestin birth control pills — the most commonly prescribed form of hormonal contraception — double the risk of ischemic stroke compared to non-use. That is the central finding of a landmark Danish study published in The BMJ in February 2025, which tracked over 2 million women aged 15 to 49 across 25 years. The pill most associated with litigation over stroke and blood clot injuries is Yaz (drospirenone and ethinyl estradiol), manufactured by Bayer, which has paid out more than $2.8 billion in settlements to thousands of women harmed by its products.
For a brain health audience, this matters enormously: ischemic stroke is not only a leading cause of disability but also one of the strongest modifiable risk factors for vascular dementia later in life. What makes this issue particularly troubling is how rarely the estrogen dose–stroke relationship gets a thorough discussion in the prescribing room. Many clinicians default to combined oral contraceptives without walking patients through the specific cardiovascular tradeoffs or mentioning safer alternatives like the levonorgestrel-releasing IUD, which the Danish study found carried no increased stroke or heart attack risk at all. This article breaks down what the research actually shows, which contraceptive methods carry the highest and lowest risk, who is most vulnerable, and what the massive legal settlements over Yaz and NuvaRing reveal about how long these dangers were underplayed.
Table of Contents
- How Much Does the Combined Birth Control Pill Increase Stroke Risk?
- Beyond the Pill — Why Patches and Vaginal Rings May Be Even Riskier
- Yaz, Yasmin, and NuvaRing — What Billions in Settlements Reveal
- Who Should Absolutely Avoid Combined Hormonal Contraceptives
- The Brain Health Connection — Why Stroke Risk Matters for Dementia Prevention
- The Safest Hormonal Option — What the Data Says About the IUD
- A Shifting Standard of Care
- Conclusion
- Frequently Asked Questions
How Much Does the Combined Birth Control Pill Increase Stroke Risk?
The 2025 Danish registry study is the largest and most comprehensive look at this question to date. Researchers followed over 2 million women from 1996 through 2021 and found that combined estrogen-progestin oral contraceptives were associated with approximately double the risk of ischemic stroke and heart attack compared to women not using hormonal contraception. In absolute terms, that translates to 1 extra stroke for every 4,760 women using the combined pill per year, and 1 extra heart attack for every 10,000 women per year of use. The absolute numbers sound small, but across millions of users worldwide, they represent thousands of preventable strokes annually. The risk is dose-dependent, and the estrogen component is the primary driver. Pills containing 20 micrograms of ethinyl estradiol were associated with a 1.9-fold increased stroke risk and a 1.6-fold increased heart attack risk.
Pills with 30 to 40 micrograms of ethinyl estradiol pushed stroke risk to 2.0 times baseline and heart attack risk to 2.1 times. A separate meta-analysis published in PMC quantified this precisely: for every 10-microgram increase in estrogen dosage, the pooled odds ratio of total stroke increases by 1.19. Notably, the type or generation of progestin in the pill does not meaningfully change the stroke risk — it is the estrogen that matters. This distinction is critical because it means that switching from one brand of combined pill to another combined pill with a different progestin does little to reduce cardiovascular danger. A woman on a 30-microgram ethinyl estradiol pill who is told her prescription is “low dose” may not realize that even this level nearly doubles her stroke risk. The only way to meaningfully reduce the hormonal contraception–stroke connection is to lower or eliminate the estrogen component entirely.
Beyond the Pill — Why Patches and Vaginal Rings May Be Even Riskier
One of the more alarming findings from the Danish study is that non-oral combined hormonal methods carry even higher cardiovascular risks than the pill itself. The contraceptive patch was associated with a 3.4-fold increased risk of ischemic stroke — the highest of any method studied. The vaginal ring, such as NuvaRing, carried a 2.4-fold stroke risk and a striking 3.8-fold increased heart attack risk. These numbers significantly exceed those of the oral combined pill. The likely explanation is pharmacokinetic.
Patches and rings deliver estrogen continuously through the skin or vaginal mucosa, bypassing the gastrointestinal tract and producing more sustained blood levels of the hormone. The estrogen component increases stroke risk by altering how the liver synthesizes clotting factor proteins, and steady-state delivery may amplify this effect compared to the peaks and troughs of a daily oral dose. Women who were switched to the patch or ring under the assumption that these are gentler or more convenient alternatives may have unknowingly taken on greater cardiovascular risk. However, if a woman has no additional stroke risk factors — she is under 35, does not smoke, has normal blood pressure, no history of migraine with aura, and no family history of clotting disorders — her absolute risk even with these methods remains relatively low. The baseline rate is roughly 8 strokes per 100,000 women per year, and doubling or tripling a small number still yields a small number. The danger escalates sharply when compounding risk factors enter the picture, which is exactly where the prescribing conversation tends to fall short.
Yaz, Yasmin, and NuvaRing — What Billions in Settlements Reveal
The legal history surrounding certain contraceptive brands tells a story that clinical data alone cannot. Bayer settled over 18,000 lawsuits alleging that Yaz and Yasmin caused blood clots, strokes, and heart attacks. As of January 2016, Bayer had paid $2.04 billion to resolve approximately 10,300 blood clot injury claims. An additional $56.9 million settled roughly 1,200 stroke and heart attack claims specifically. In late 2024, a further $750 million settlement was paid to 3,490 additional claimants. These are not theoretical risks debated in medical journals — they are real injuries, adjudicated in courts, compensated in the billions.
Yaz and Yasmin contain drospirenone, a progestin with anti-androgenic properties that was marketed heavily for its cosmetic benefits — clearer skin, less bloating. But drospirenone-containing pills also carry a unique risk of hyperkalemia, or dangerously elevated potassium, which can be fatal for women with kidney, liver, or adrenal disease. The marketing emphasis on lifestyle benefits arguably obscured the cardiovascular and metabolic risks that accompanied the formulation. NuvaRing followed a similar trajectory. Women using the vaginal ring experienced thrombotic strokes at a rate 2.5 times higher than non-users. Merck ultimately settled the NuvaRing multidistrict litigation class action for $100 million, with the MDL closing in September 2021. In both cases, the pattern was the same: widespread prescribing, underemphasized risks, serious injuries, and eventual legal accountability that came years too late for the women affected.
Who Should Absolutely Avoid Combined Hormonal Contraceptives
Not all women face equal risk, and certain combinations of factors make combined estrogen-progestin methods genuinely dangerous. The most well-established contraindication is smoking in women over age 35. This combination dramatically increases the risk of blood clots, stroke, and heart attack, and most prescribing guidelines explicitly warn against it. Yet enforcement of this guideline is inconsistent, and some women continue to receive combined prescriptions despite meeting this criteria. Migraine with aura is another major red flag.
The American Migraine Foundation and most international guidelines consider combined oral contraceptives generally contraindicated for women who experience migraine with aura, because the combination substantially elevates ischemic stroke risk. Women with high blood pressure, diabetes, high cholesterol, or obesity also face compounding cardiovascular danger when adding exogenous estrogen. For this population, progestin-only pills, the hormonal IUD, or non-hormonal methods represent meaningfully safer choices — yet these alternatives are often presented as secondary options rather than first-line recommendations. The tradeoff is real: combined pills tend to be more effective at managing acne, menstrual regularity, and certain hormonal symptoms than progestin-only alternatives. But the cardiovascular cost of that additional estrogen, particularly for women with any of the risk factors above, is a tradeoff that deserves an honest, informed conversation — not a footnote in a patient handout.
The Brain Health Connection — Why Stroke Risk Matters for Dementia Prevention
For readers of a brain health and dementia care site, the stroke risk associated with hormonal contraceptives is not merely a cardiovascular concern — it is a cognitive one. Ischemic stroke is one of the strongest known risk factors for vascular dementia, the second most common form of dementia after Alzheimer’s disease. Even so-called “silent” strokes — small vessel events that produce no obvious symptoms — can accumulate over time and contribute to cognitive decline, memory loss, and executive dysfunction decades later. A woman who suffers a stroke in her 20s or 30s from a contraceptive-related clotting event faces not only the immediate consequences of that stroke but also a significantly elevated lifetime risk of vascular cognitive impairment.
The brain does not fully recover from ischemic injury, and the affected tissue becomes a site of permanent vulnerability. This is why stroke prevention at every age matters for long-term brain health, and why a doubled stroke risk — even when the absolute numbers seem modest — deserves serious weight in contraceptive decision-making. The limitation here is that no study has directly tracked women from contraceptive-related stroke to later dementia diagnosis over a multi-decade follow-up. The connection is inferred from what we know about stroke as a dementia risk factor and the established link between combined hormonal contraceptives and ischemic stroke. But the biological plausibility is strong, and the precautionary principle argues for minimizing avoidable stroke risk whenever safe alternatives exist.
The Safest Hormonal Option — What the Data Says About the IUD
Among all hormonal contraceptive methods evaluated in the 2025 Danish study, the levonorgestrel-releasing IUD stood alone as the only option associated with no increased risk of stroke or heart attack. This is because the IUD delivers progestin locally to the uterus, with minimal systemic hormone absorption and no estrogen component.
For women who want reliable hormonal contraception without cardiovascular risk, the hormonal IUD is the evidence-based choice. Progestin-only pills and implants also fared better than combined methods, carrying slightly elevated but substantially lower risk than estrogen-containing options. For women who cannot or prefer not to use an IUD, progestin-only oral contraceptives represent a reasonable middle ground — though they require stricter timing for daily doses and may cause more irregular bleeding than combined pills.
A Shifting Standard of Care
The accumulation of evidence — from the Danish registry study to the dose-response meta-analyses to the billions paid in legal settlements — points toward a medical culture that has been slow to update its default prescribing habits. Combined oral contraceptives were revolutionary when introduced in the 1960s, and they remain effective and appropriate for many women.
But the reflexive prescribing of estrogen-containing pills as the default first option, without a thorough discussion of estrogen dose, individual risk factors, and safer alternatives, is increasingly difficult to defend. The 2025 BMJ data should accelerate a shift that has been overdue: toward individualized prescribing that weighs cardiovascular risk honestly, toward greater use of progestin-only and IUD options as first-line methods for women with any compounding risk factors, and toward conversations in which stroke — and its long-term implications for brain health — is not treated as a footnote but as a central consideration.
Conclusion
Combined estrogen-progestin birth control pills double the risk of ischemic stroke, with higher estrogen doses and non-oral delivery methods like the patch and vaginal ring carrying even greater danger. The risk is real and dose-dependent, driven almost entirely by the estrogen component, and compounded significantly by smoking, age over 35, migraine with aura, and other cardiovascular risk factors. For brain health specifically, any avoidable increase in stroke risk carries implications that extend far beyond the event itself — ischemic injury to the brain is permanent and contributes to long-term cognitive decline and vascular dementia.
If you are currently taking a combined hormonal contraceptive, the most important step is an informed conversation with your prescriber about your individual risk profile. Ask specifically about the estrogen dose in your pill, whether you have any compounding risk factors, and whether a progestin-only pill or levonorgestrel-releasing IUD might be appropriate for you. These alternatives provide effective contraception without the cardiovascular tradeoffs. The evidence is clear — the question is whether the conversation is happening.
Frequently Asked Questions
Do all birth control pills increase stroke risk?
No. The increased risk is driven by the estrogen component in combined pills. Progestin-only pills carry a much smaller increase in risk, and the levonorgestrel-releasing IUD showed no increased stroke or heart attack risk in the 2025 Danish study of over 2 million women.
How much does the combined pill actually increase stroke risk?
Combined estrogen-progestin pills approximately double the risk of ischemic stroke compared to non-use. In absolute terms, this translates to about 1 extra stroke per 4,760 women using the combined pill per year. The risk increases with higher estrogen doses — for every 10-microgram increase in ethinyl estradiol, the odds ratio of stroke increases by 1.19.
Is the patch or ring safer than the pill?
No — the 2025 Danish study found them riskier. The contraceptive patch was associated with a 3.4-fold increased ischemic stroke risk, and the vaginal ring (such as NuvaRing) with a 2.4-fold stroke risk and 3.8-fold heart attack risk, both exceeding the risk associated with oral combined pills.
What makes Yaz and Yasmin particularly concerning?
Bayer paid over $2.8 billion in settlements to resolve more than 18,000 lawsuits alleging these drospirenone-containing pills caused blood clots, strokes, and heart attacks. Drospirenone also carries a unique risk of hyperkalemia, which can be fatal for women with kidney, liver, or adrenal disease.
Can birth control-related stroke increase dementia risk later in life?
Ischemic stroke is one of the strongest known risk factors for vascular dementia. While no study has directly followed women from contraceptive-related stroke to dementia diagnosis decades later, the biological link between ischemic brain injury and long-term cognitive decline is well established.
What is the safest hormonal contraceptive for cardiovascular health?
The levonorgestrel-releasing IUD was the only hormonal contraceptive in the 2025 Danish study associated with no increased risk of stroke or heart attack. It delivers progestin locally with minimal systemic absorption and contains no estrogen.
You Might Also Like
- Why Chemotherapy Hair Loss Is Temporary for Most — But Not All
- Why ADHD Medication Works for Some Adults but Not Others
- The Side Effect of Cancer Treatment That Lasts for Decades
For more, see Alzheimer’s Association — caregiving.
